Sugi Predict

Sugi Predict / Compounds / SCHEMBL4471265

SCHEMBL4471265

SCHEMBL4471265

Cc1[nH]c(C(=O)O)c(C)c1C(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.51
▸ ALDH1A1 P00352 6/20 0.51
▸ HPGD P15428 1/20 0.51
▸ NPC1 O15118 7/20 0.49
▸ SMN1; SMN2 Q16637 6/20 0.49
▸ MAPT P10636 4/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ SENP8 Q96LD8 1/20 0.49
▸ SENP7 Q9BQF6 1/20 0.49
▸ SENP6 Q9GZR1 1/20 0.49
▸ CREBBP Q92793 1/20 0.48
▸ LMNA P02545 4/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KMT2A Q03164 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ SRD5A2 P31213 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197087 0.88 CYP1A2 (0.61) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL16256718 0.85 POLB (0.53) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL4471417 0.83 ALDH1A1 (0.44) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL15151532 0.83 CREBBP (0.47) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
Oxindole SCHEMBL28593104 0.82 AHR (0.50) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL257220 0.81 RAB9A (0.79) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL15151577 0.81 CREBBP (0.45) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL15151382 0.81 CES2 (0.50) RAB9AALDH1A1HPGDNPC1SMN1; SMN2
SCHEMBL15151625 0.80 TP53 (0.57) ALDH1A1MAPTCREBBPKMT2APOLB
SCHEMBL15151427 0.79 KMO (0.49) RAB9AALDH1A1HPGDNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572924-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2009-08-11 — — US disclosed
US-7320996-B2 Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer SUGEN, INC (US) 2008-01-22 — — US disclosed
CN-1329390-C Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN INC (US) 2007-08-01 — — CN disclosed
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2007-01-11 — — US disclosed
US-7125905-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2006-10-24 — — US disclosed
US-20050176802-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2005-08-11 — — US disclosed
EP-1427326-A4 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN INC (US) 2005-06-08 — — EP disclosed
US-6878733-B1 Formulations for pharmaceutical agents ionizable as free acids or free bases SUGEN, INC. (US) 2005-04-12 — — US disclosed
CN-1541098-A Combination therapy for treatment of cancer �ո��� 2004-10-27 — — CN disclosed
EP-1427326-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Sugen, Inc. (US) 2004-06-16 — — EP disclosed
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2004-04-01 — — US disclosed
US-20030216410-A1 Combination therapy for the treatment of cancer PHARMACIA CORPORATION 2003-11-20 — — US disclosed
CN-1439005-A Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN INC (US) 2003-08-27 — — CN disclosed
US-6573293-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-03 — — US disclosed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 — — WO disclosed
EP-1255752-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2002-11-13 — — EP disclosed
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PHARMACIA & UPJOHN COMPANY LLC 2002-10-24 — — US disclosed
WO-2001060814-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216410-A1 Combination therapy for the treatment of cancer PTGS2, PTGES2, PTGFR RAB9A 4613/4885ALDH1A1 918/4885HPGD 60/4885
US-20050176802-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 RAB9A 1276/4885ALDH1A1 2793/4885HPGD 1053/4885
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, PLK2, PNCK RAB9A 1328/4885ALDH1A1 2848/4885HPGD 1010/4885
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 RAB9A 1276/4885ALDH1A1 2793/4885HPGD 1053/4885
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 RAB9A 1276/4885ALDH1A1 2793/4885HPGD 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.